The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity
Abstract
Objectives To evaluate the efficacy and safety of ianalumab (VAY736), a B cell-depleting, B cell activating factor receptor-blocking, monoclonal antibody, in patients with active primary Sjögren’s syndrome (pSS) in a double-blind, placebo-controlled, phase II, single-centre study. Methods Patients with pSS, EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) ≥6, were randomised to ianalumab single infusion at either 3 mg/kg (n=6), 10 mg/kg (n=12) or placebo (n=9). Outcomes were measured blinded at baseline and weeks 6, 12, 24, and unblinded at end of study (EoS) when B cell numbers had recovered. Clinical outcomes included ESSDAI, EULAR Sjögren’s Syndrome Patient Reported Index (ESSPRI), salivary flow rate, ocular staining score, physician global assessment and patient assessments of fatigue and general quality of life. Laboratory-based measures included circulating leucocyte subsets and markers of B cell activity. Results A similar trend showing positive therapeutic effect by ianalumab was observed across the primary clinical outcome (ESSDAI) and all secondary clinical outcomes (ESSPRI, Multidimensional Fatigue Inventory, Short Form-36, global assessments by physician and patient) versus the placebo-treated group. Rapid and profound B cell depletion of long-lasting duration occurred after a single infusion of ianalumab at either dose. Serum Ig light chains decreased, with return to baseline levels at EoS. Changes in some clinical outcomes persisted through to EoS in the higher dose group. Adverse effects were largely limited to mild to moderate infusion reactions within 24 hours of ianalumab administration. Conclusions Overall results in this single-dose study suggest potent and sustained B cell depletion by ianalumab could provide therapeutic benefits in patients with pSS without major side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meijer, J. M., Meiners, P. M., Vissink, A., Spijkervet, F. K. L., Abdulahad, W., Kamminga, N., Brouwer, E., Kallenberg, C. G. M., & Bootsma, H. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27314 · Cited by 488
Treatment of Primary Sjögren Syndrome With Rituximab: A Randomized Trial
Devauchelle-Pensec, V., Mariette, X., Jousse-Joulin, S., Berthelot, J.-M., Perdriger, A., Puéchal, X., Le Guern, V., Sibilia, J., Gottenberg, J.-E., Chiche, L., et al. (2014) · Annals of Internal Medicine · doi:10.7326/m13-1085 · Cited by 429
Bowman, S. J., Everett, C. C., O'Dwyer, J. L., Emery, P., Pitzalis, C., Ng, W., Pease, C. T., Price, E. J., Sutcliffe, N., Gendi, N. S. T., et al. (2017) · Arthritis & Rheumatology · doi:10.1002/art.40093 · Cited by 276
Cited by
B cell depletion therapies in autoimmune disease: advances and mechanistic insights
Lee, D. S. W., Rojas, O. L., & Gommerman, J. L. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00092-2 · Cited by 658
Novel paradigms in systemic lupus erythematosus
Dörner, T., & Furie, R. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30546-x · Cited by 565
Self-citationPhage Display Derived Monoclonal Antibodies: From Bench to Bedside
Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01986 · Cited by 273
The Role of B Cells and B Cell Therapies in Immune-Mediated Liver Diseases
Cargill, T., & Culver, E. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.661196 · Cited by 46
“Inalumab has recently shown safety and efficacy in a phase II trial in individuals with primary Sjögren’s syndrome, a B cell mediated autoimmune disease involving exocrine glands (164) and has been used successfully to induce remission in 2 reported cases of difficult to treat AIH (165).”
BackgroundImpact of B‐cell‐targeted therapies on cardiovascular disease
Porsch, F., & Binder, C. J. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.311996 · Cited by 29
Metadata
- Authors
- Dörner, T., Posch, M. G., Li, Y., Petricoul, O., Cabanski, M., Milojevic, J. M., Kamphausen, E., Valentin, M.-A., Simonett, C., Mooney, L., Hüser, A., Gram, H., Wagner, F. D., & Oliver, S. J.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2019-05
- Volume
- 78
- Issue
- 5
- Pages
- 641-647
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2918203828
- Cited by
- 192
- References
- 3
- FWCI
- 12.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. https://app.cochat.ai/papers/10.1136/annrheumdis-2018-214720
- The paper
- Dörner, T., Posch, M. G., Li, Y., Petricoul, O., Cabanski, M., Milojevic, J. M., Kamphausen, E., Valentin, M.-A., Simonett, C., Mooney, L., Hüser, A., Gram, H., Wagner, F. D., & Oliver, S. J. (2019). Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2018-214720
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.